12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Riociguat: Phase III data

The double-blind, international Phase III CHEST-1 trial in 261 patients with inoperable CTEPH or with persistent or recurrent pulmonary hypertension after pulmonary endarterectomy showed that riociguat met the primary endpoint of improving 6MWT distance from baseline to week 16 vs. placebo. Specifically, riociguat led to a placebo-adjusted improvement in 6MWT distance of 46 meters from baseline to week 16 (p<0.0001). Riociguat also met the secondary endpoints of improving PVR (p<0.0001), NT-proBNP levels (p<0.0001)...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >